Logo image of QTTB

Q32 BIO INC (QTTB) Stock Overview

NASDAQ:QTTB - US7469641051 - Common Stock

1.71 USD
-0.06 (-3.39%)
Last: 8/29/2025, 8:00:01 PM
1.71 USD
0 (0%)
After Hours: 8/29/2025, 8:00:01 PM

QTTB Key Statistics, Chart & Performance

Key Statistics
52 Week High53.79
52 Week Low1.35
Market Cap20.86M
Shares12.20M
Float9.15M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-4.3
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05
IPO03-28 2018-03-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


QTTB short term performance overview.The bars show the price performance of QTTB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

QTTB long term performance overview.The bars show the price performance of QTTB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of QTTB is 1.71 USD. In the past month the price decreased by -14.5%. In the past year, price decreased by -96.07%.

Q32 BIO INC / QTTB Daily stock chart

QTTB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About QTTB

Company Profile

QTTB logo image Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts and currently employs 27 full-time employees. The company went IPO on 2018-03-28. The company focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). The company has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.

Company Info

Q32 BIO INC

830 Winter Street

Waltham MASSACHUSETTS US

Employees: 27

QTTB Company Website

QTTB Investor Relations

Phone: 17819990232

Q32 BIO INC / QTTB FAQ

What is the stock price of Q32 BIO INC today?

The current stock price of QTTB is 1.71 USD. The price decreased by -3.39% in the last trading session.


What is the ticker symbol for Q32 BIO INC stock?

The exchange symbol of Q32 BIO INC is QTTB and it is listed on the Nasdaq exchange.


On which exchange is QTTB stock listed?

QTTB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for Q32 BIO INC stock?

10 analysts have analysed QTTB and the average price target is 10.2 USD. This implies a price increase of 496.49% is expected in the next year compared to the current price of 1.71. Check the Q32 BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is Q32 BIO INC worth?

Q32 BIO INC (QTTB) has a market capitalization of 20.86M USD. This makes QTTB a Nano Cap stock.


How many employees does Q32 BIO INC have?

Q32 BIO INC (QTTB) currently has 27 employees.


What are the support and resistance levels for Q32 BIO INC (QTTB) stock?

Q32 BIO INC (QTTB) has a support level at 1.62 and a resistance level at 3.15. Check the full technical report for a detailed analysis of QTTB support and resistance levels.


Should I buy Q32 BIO INC (QTTB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does Q32 BIO INC (QTTB) stock pay dividends?

QTTB does not pay a dividend.


When does Q32 BIO INC (QTTB) report earnings?

Q32 BIO INC (QTTB) will report earnings on 2025-11-05.


What is the Price/Earnings (PE) ratio of Q32 BIO INC (QTTB)?

Q32 BIO INC (QTTB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.3).


What is the Short Interest ratio of Q32 BIO INC (QTTB) stock?

The outstanding short interest for Q32 BIO INC (QTTB) is 4.51% of its float. Check the ownership tab for more information on the QTTB short interest.


QTTB Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to QTTB. When comparing the yearly performance of all stocks, QTTB is a bad performer in the overall market: 96.98% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

QTTB Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to QTTB. QTTB may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

QTTB Financial Highlights

Over the last trailing twelve months QTTB reported a non-GAAP Earnings per Share(EPS) of -4.3. The EPS increased by 86.42% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -75.58%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%45.07%
Sales Q2Q%N/A
EPS 1Y (TTM)86.42%
Revenue 1Y (TTM)-100%

QTTB Forecast & Estimates

10 analysts have analysed QTTB and the average price target is 10.2 USD. This implies a price increase of 496.49% is expected in the next year compared to the current price of 1.71.


Analysts
Analysts78
Price Target10.2 (496.49%)
EPS Next Y82.51%
Revenue Next YearN/A

QTTB Ownership

Ownership
Inst Owners54.94%
Ins Owners0.61%
Short Float %4.51%
Short Ratio0.26